Key terms
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RYTM news
Apr 18
6:45am ET
Wells Fargo Remains a Buy on Rhythm Pharmaceuticals (RYTM)
Apr 16
5:32am ET
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)
Apr 01
8:19am ET
Rhythm Pharmaceuticals secures $150M in convertible preferred stock financing
Mar 26
6:20am ET
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
Mar 25
8:15am ET
Rhythm announces first patient dosed in Phase 1 trial of RM-718
Feb 23
8:26am ET
Rhythm Pharmaceuticals: Expanding Markets and Innovation Fuel Buy Rating Upgrade
Feb 23
6:19am ET
3 Best Stocks to Buy Now, 2/23/2024, According to Top Analysts
Feb 22
2:25pm ET
Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Strong Imcivree Performance and Market Expansion
Feb 22
1:17pm ET
Stifel ups Rhythm Pharmaceuticals target, calls pullback buying opportunity
Feb 22
12:35pm ET
Buy Rating Affirmed for Rhythm Pharmaceuticals Amidst Growth Potential Despite Quarterly Sales Variability
Feb 22
7:47am ET
Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Strong Prescription Growth and Promising Clinical Developments
Feb 22
7:28am ET
Rhythm Pharmaceuticals announces development plan of setmelanotide
Feb 22
7:12am ET
Rhythm Pharmaceuticals Announces Upcoming Financial Control Deficiencies
Feb 22
7:09am ET
Rhythm Pharmaceuticals announces upcoming milestones
Feb 22
7:08am ET
Rhythm Pharmaceuticals reports Q4 EPS (70c), consensus (70c)
Feb 09
8:28am ET
Stifel Nicolaus Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
Feb 09
8:16am ET
Buy Rating for Rhythm Pharmaceuticals: Anticipated Growth and Strong Performance Led by IMCIVREE in BBS Market
Feb 07
8:15am ET
Rhythm Pharmaceuticals announces reimbursement decision in Italy for IMCIVREE
Jan 26
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 26
5:55am ET
Buy Rating Reaffirmed for Rhythm Pharmaceuticals Amid Stable Sales Projections and Strong Product Outlook
No recent press releases are available for RYTM
RYTM Financials
Key terms
Ad Feedback
RYTM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RYTM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range